About Hitgen Inc. Company

The company is committed to building a world-class innovative biomedical enterprise. It is headquartered in Chengdu, China. Through diversified business models such as new drug research and development services, transfer of research projects at different stages, and long-term drug marketing, the company has established cooperation with hundreds of pharmaceutical companies, biotechnology companies, chemical companies, foundations and scientific research institutions around the world. Currently, the company has several internal new drug projects in different clinical and pre-clinical stages. The company focuses on the discovery and optimization of new small molecule and nucleic acid drugs, and relies on DEL technology (including design, synthesis, screening and expanded application of DEL libraries), drug design (FBDD/SBDD) technology based on molecular fragments and three-dimensional structural information, oligonucleotide-based drug development platforms (OBT), targeted protein degradation platform related technology (TPD), and the company's other key new drug development capabilities (pharmaceutical chemistry, computational science/AI, in vitro biological evaluation, pharmacometabolism, analytical chemistry, pharmaceutical research, etc.). The company's main products and services include drug development and technical consulting, technology transfer and technical services. Corporate honors: Chengdu Pioneer has been awarded the “CASREGISTRYINNOVATOR” certificate by the Chemical Abstracts Service of the American Chemical Society twice.